Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GE and Geron to work on embryonic stem cell assays

This article was originally published in Clinica

Executive Summary

GE Healthcare is to partner with pharmaceutical firm Geron in the development of cellular assays for use in drug discovery, drug development and toxicity screening. As part of an exclusive global alliance, scientists from the two companies will work on assay products derived from human embryonic stem cells (hESCs). GE will fund the research and development process for the assays, and will also be responsible for the manufacturing, sales and distribution of the resulting products. Financial terms of the deal were not disclosed. According to GE, the partnership with Geron is designed to improve early in vitro screening of drug candidates and, in turn, reduce both overall drug development costs and potentially harmful patient exposure during clinical trials.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT043696

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel